1 week Ago By Defense World Staff
Trexquant Investment LP reduced its position in shares of Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 70.7% in the fourth quarter, according to its most recent filing with the SEC.
The fund owned 19,147 shares of the company’s stock after selling 46,127 shares during the quarter. Trexquant Investment LP’s holdings in Bausch + Lomb were worth $346,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently modified their holdings of the business.
Charles Schwab Investment Management Inc. lifted its position in Bausch + Lomb by 80.8% during the third quarter.
Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock valued at $576,000 after purchasing an additional 13,302 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Bausch + Lomb during the 3rd quarter valued at approximately $302,000.
HighTower Advisors LLC raised its holdings in Bausch + Lomb by 14.7% during the 3rd quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock valued at $476,000 after buying an additional 3,164 shares during the period.
State Street Corp lifted its position in Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company’s stock worth $549,000 after buying an additional 1,510 shares during the last quarter.
Finally, XTX Topco Ltd purchased a new position in Bausch + Lomb during the third quarter worth $309,000. 11.07% of the stock is owned by hedge funds and other institutional investors.
Bausch + Lomb Trading Up 0.6 %NYSE BLCO opened at $11.39 on Monday.
The company’s 50-day simple moving average is $15.05 and its two-hundred day simple moving average is $17.59.
Bausch + Lomb Co. has a one year low of $10.46 and a one year high of $21.
69. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of -12.
52, a price-to-earnings-growth ratio of 0.85 and a beta of 0.54.
The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.
60. Bausch + Lomb (NYSE:BLCO – Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $0.
25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02.
Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%.
The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion.
During the same quarter in the prior year, the business earned $0.24 earnings per share. Bausch + Lomb’s revenue was up 9.
1% on a year-over-year basis. Equities analysts forecast that Bausch + Lomb Co. will post 0.
74 EPS for the current fiscal year. Analyst Ratings ChangesA number of equities analysts recently commented on the stock. Bank of America dropped their price target on shares of Bausch + Lomb from $18.
00 to $17.00 and set an “underperform” rating for the company in a research note on Thursday, February 20th. Stifel Nicolaus cut their target price on Bausch + Lomb from $17.
00 to $15.00 and set a “hold” rating on the stock in a research note on Thursday, April 3rd. HC Wainwright reissued a “buy” rating and set a $23.
00 price target on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Royal Bank of Canada dropped their price objective on Bausch + Lomb from $18.00 to $17.
00 and set an “outperform” rating for the company in a report on Friday, April 4th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock.
Based on data from MarketBeat.com, Bausch + Lomb currently has a consensus rating of “Hold” and a consensus price target of $18.82.
Get Our Latest Stock Report on Bausch + LombBausch + Lomb Company Profile (Free Report)Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Further ReadingFive stocks we like better than Bausch + LombRussell 2000 Index, How Investors Use it For Profitable TradingIs McDonald’s Stock Serving a Value Meal to Investors? CD Calculator: Certificate of Deposit Calculator Walgreens Comeback? Private Equity Circling for a BuyoutWhat Investors Must Know About Over-the-Counter (OTC) StocksCoca-Cola Stock Looks Refreshing After the Relief Rally.
